Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab in Relapsed/Refractory B-cell NHL
NCT01647971Phase 2Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Jul 2012
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ublituximab in B cell lymphoma, chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), sponsored by TG Therapeutics, Inc.. Started Jul 2012; status: completed.
02
Drugs
ublituximab
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)Waldenstrom macroglobulinemia (WM)marginal zone lymphoma (MZL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01647971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01647971.